Semaglutide targets GLP-1 only
These systemic changes, along with the documented heart rate effects, may contribute to cardiovascular sensations as the body adapts to treatment

These drugs also have low uptake (less than 2% in the USA) due to several factors, including patients reluctance to seek treatment, lack of addiction training among healthcare providers and considerable stigma surrounding AUD and addiction. - Lorenzo Leggio, et al, Nature Medicine, December 2023 Based on the percentage of people in the United States with alcohol use disorder (11% or ~29.5 million) and the number of people who have received medication for alcohol use disorder in the past year (624,000) and the number of people taking GLP-1 drugs (7 percent of American adults or 18 million), we roughly estimate that more than 3 times as many people with AUD have been incidentally prescribed a GLP-1 in the past year than have been prescribed a medication that is FDA indicated for alcohol use disorder (~2 million vs 624,000, and these groups may overlap)

These compounded medications are made by state-licensed pharmacies that follow both federal and state regulations, including quality standards
There are different kinds of compounding pharmacies: 503A Pharmacies: These compound medications based on individual patient prescriptions